Foghorn Therapeutics annual revenue
2020
2021
2022
2023
2024
2025
Foghorn Therapeutics Revenue Growth & History (FHTX)
Foghorn Therapeutics reported $30.9M in revenue for fiscal 2025, an increase of 36.75% from the previous fiscal year.
View full Foghorn Therapeutics company overviewFoghorn Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $30.9M | $8.3M | +36.75% |
| 2024 | 2024-12-31 | $22.6M | −$11.6M | −33.83% |
| 2023 | 2023-12-31 | $34.2M | $14.9M | +77.63% |
| 2022 | 2022-12-31 | $19.2M | $17.9M | +1357.77% |
| 2021 | 2021-12-31 | $1.3M | $889,000 | +206.74% |
| 2020 | 2020-12-31 | $430,000 | — | — |
Foghorn Therapeutics quarterly revenue
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $16.1M | $8.5M | +112.68% |
| Q1 2026 | 2026-03-31 | $3.3M | −$2.7M | −45.11% |
| Q4 2025 | 2025-12-31 | $9.2M | $6.4M | +223.77% |
| Q3 2025 | 2025-09-30 | $8.2M | $345,000 | +4.42% |
| Q2 2025 | 2025-06-30 | $7.6M | $669,000 | +9.71% |
| Q1 2025 | 2025-03-31 | $6.0M | $902,000 | +17.86% |
| Q4 2024 | 2024-12-31 | $2.9M | −$2.9M | −50.49% |
| Q3 2024 | 2024-09-30 | $7.8M | −$9.7M | −55.33% |
| Q2 2024 | 2024-06-30 | $6.9M | $1.3M | +23.02% |
| Q1 2024 | 2024-03-31 | $5.0M | −$259,000 | −4.88% |
| Q4 2023 | 2023-12-31 | $5.8M | $1.6M | +37.88% |
| Q3 2023 | 2023-09-30 | $17.5M | $10.8M | +163.46% |
| Q2 2023 | 2023-06-30 | $5.6M | $1.1M | +24.70% |
| Q1 2023 | 2023-03-31 | $5.3M | $1.4M | +35.43% |
| Q4 2022 | 2022-12-31 | $4.2M | $3.5M | +486.82% |
| Q3 2022 | 2022-09-30 | $6.6M | $6.6M | +16080.49% |
| Q2 2022 | 2022-06-30 | $4.5M | $4.2M | +1509.32% |
| Q1 2022 | 2022-03-31 | $3.9M | $3.6M | +1270.63% |
| Q4 2021 | 2021-12-31 | $713,000 | $462,000 | +184.06% |
| Q3 2021 | 2021-09-30 | $41,000 | −$138,000 | −77.09% |
| Q2 2021 | 2021-06-30 | $279,000 | $279,000 | — |
| Q1 2021 | 2021-03-31 | $286,000 | $286,000 | — |
| Q4 2020 | 2020-12-31 | $251,000 | — | — |
| Q3 2020 | 2020-09-30 | $179,000 | — | — |
| Q2 2020 | 2020-06-30 | $0 | — | — |
| Q1 2020 | 2020-03-31 | $0 | — | — |
Foghorn Therapeutics revenue growth trends
Over the last five reported fiscal years, revenue grew from $430,000 to $30.9M, a compound annual growth rate of 135.14%. Foghorn Therapeutics's latest reported quarter, Q2 2026, generated $16.1M in revenue, an increase of 112.68% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Foghorn Therapeutics source filings ↗